SCHEMBL7187544

SCHEMBL7187544

Cc1c(C)c(C(=O)c2ccccc2)c(C)c([PH](=O)C(=O)c2c(C(F)(F)F)cccc2C(F)(F)F)c1C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 1/20 0.38
NR1H3 Q13133 1/20 0.38
TAS2R14 Q9NYV8 1/20 0.37
HTT P42858 2/20 0.35
GFER P55789 1/20 0.34
RORC P51449 3/20 0.34
KCNK3 O14649 2/20 0.34
KCNK9 Q9NPC2 2/20 0.34
ALDH1A1 P00352 4/20 0.33
MAPT P10636 3/20 0.33
LMNA P02545 2/20 0.33
CYP2C9 P11712 2/20 0.33
HSD17B10 Q99714 2/20 0.33
MEN1 O00255 2/20 0.33
CYP1A2 P05177 2/20 0.33
KMT2A Q03164 2/20 0.33
CYP3A4 P08684 2/20 0.33
POLB P06746 1/20 0.33
HPGD P15428 1/20 0.33
CYP2C19 P33261 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7180924 0.97 NR1H2 (0.39) NR1H2NR1H3TAS2R14HTTGFER
SCHEMBL7186789 0.85 NR1H2 (0.37) NR1H2NR1H3TAS2R14RORCKCNK3
SCHEMBL7735674 0.84 MAOB (0.36) NR1H2NR1H3TAS2R14HTTALDH1A1
SCHEMBL7180485 0.83 NR1H2 (0.40) NR1H2NR1H3TAS2R14RORCKCNK3
SCHEMBL7177292 0.83 HTT (0.38) HTTGFERALDH1A1MAPTLMNA
SCHEMBL7175295 0.82 NR1H2 (0.41) NR1H2NR1H3TAS2R14RORCKCNK3
SCHEMBL7175608 0.81 ALDH1A1 (0.42) HTTGFERRORCALDH1A1MAPT
SCHEMBL7178033 0.80 HTT (0.40) HTTGFERALDH1A1MAPTLMNA
SCHEMBL7181381 0.80 MRGPRX4 (0.37) NR1H2NR1H3HTTRORCKCNK3
SCHEMBL7181661 0.79 CA12 (0.43) HTTALDH1A1MAPTLMNAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 NR1H2 63/4885NR1H3 41/4885TAS2R14 2184/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 NR1H2 95/4885NR1H3 64/4885TAS2R14 2410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.